The China National Medical Products Administration approved the New Drug Application for Zejula (niraparib), an oral, once-daily poly (ADP-ribose) polymerase inhibitor as maintenance therapy for adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
The Cancer Letter has covered—and will continue to cover—all the ways in which the current administration is fundamentally reshaping cancer research in the U.S. But this week, The Cancer Letter and the podcast focused on a patient story.
